News | September 27, 2022
Novartis unveils new focused strategy
Transformation to pure-play Innovative Medicines company nears completion
Transformation to pure-play Innovative Medicines company nears completion
Singapore presents great opportunities for the adoption of technology in healthcare and is open for investments
Lynparza is the first and only approved PARPi targeting BRCA-mutated HER2-negative high-risk early breast cancer
Elacestrant, if approved, would be the first oral selective estrogen receptor degrader (SERD) to be available for patients suffering from second-line (2L) and third-line (3L) ER+/HER2- advanced or metastatic breast cancer in the European Union
The decision is based on the outcome of a prespecified interim analysis of the Phase 3 AMEERA-5 trial
Results consistent with previous trials, reinforcing benefit of Daiichi Sankyo and AstraZeneca’s ENHERTU in previously treated patients
Intended for potential treatment of ER+/HER2- advanced or metastatic breast cancer patients
Acceptance based on results from the phase 3 KEYNOTE-091 trial
During the research term, Olema will contribute funding to Aurigene to facilitate ongoing discovery efforts.
Immune-mediated events and infusion reactions were higher with KEYTRUDA (38% vs 9%, respectively).
Subscribe To Our Newsletter & Stay Updated
